T2c-001 (t2cure)

N/A

Report date: 2022/12/25 13:45:24

Base Information

Drug NameT2c-001 (t2cure)

Drug Alias NameAutologous bone marrow-derived mononuclear cell fractiont2c001-SWt2c001t2c001-CHDt2c001-DCM +[6]

ClassificationCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsHeart Failure

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesT2cure University Hospital Frankfurt

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Frankfurt

Inactive CompaniesN/A

Active IndicationsHeart Failure

Inactive IndicationsN/A

Other Information

ATC CodeN/A